High frequency of unrecognized indolent hematological disorders among HLA-matched siblings of patients with lymphoproliferative malignancies eligible for allo-SCT

MeSH terms

• Clinical Trials, Phase I as Topic
• Donor Selection*
• Female
• Hematologic Neoplasms / etiology*
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
• Lymphoma, Non-Hodgkin / therapy*
• Male
• Neoplasms, Second Primary / etiology*
• Neoplastic Stem Cells / transplantation
• Pedigree
• Retrospective Studies
• Siblings*
• Stem Cell Transplantation
• Tissue Donors*
• Transplantation, Homologous